Can-Fite BioPharma vs RedHill Biopharma
CANF and RDHL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CANF and RDHL compare
Can-Fite BioPharma grew revenue faster over the last twelve months (−39.9% versus −96.4% for RedHill Biopharma).
Can-Fite BioPharma scores higher on the StockData Score (1 against 0 for RedHill Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CANF | RDHL |
|---|---|---|
| Size and price | ||
| Share price | $1.49 | $0.381 |
| Change, 1 year | −81.2% | −62.6% |
| Change, 5 years | −99.4% | −100.0% |
| Beta (5Y) | 1.10 | 1.70 |
| Employees | 5 | 13 |
| StockData Score | ||
| Total score | 1 (better) | 0 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −39.9% (better) | −96.4% |
| Revenue growth, 5Y average | −11.9% (better) | −66.2% |
| Profitability | ||
| Operating margin | −2457% (better) | −2777% |
| Net margin | −2427% | – |
| FCF margin | −2210% (better) | −3376% |
| Return on equity | −217% | – |
| Financial health | ||
| Interest coverage | −35.0× | −5.5× (better) |
| Current ratio | 3.60 (better) | 0.34 |
| Piotroski F-score | 2 | – |
| Ownership | ||
| Held by institutions | 1.9% | 0.00% |
| Held by insiders | 0.00% | 4.4% |
| Insider net buying, 12 months | – | −$1.4K |
Go deeper
- CANF stock overview
- CANF income statement
- CANF valuation and score
- RDHL stock overview
- RDHL income statement
- RDHL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.